Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shenzhenlubris Pharmaceuticals Co (SZSE:002294) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Shenzhenlubris Pharmaceuticals Co EBITDA Margin % Related Terms
Shenzhenlubris Pharmaceuticals Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhenlubris Pharmaceuticals Co EBITDA Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhenlubris Pharmaceuticals Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhenlubris Pharmaceuticals Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shenzhenlubris Pharmaceuticals Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Shenzhenlubris Pharmaceuticals Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhenlubris Pharmaceuticals Co (SZSE:002294) has a EBITDA Margin % of 21.14% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shenzhenlubris Pharmaceuticals Co and its competitors. This is 29% below median its historical median of 29.89. Over the past decade, Shenzhenlubris Pharmaceuticals Co's EBITDA Margin % has ranged from 11.70 to 46.00. According to the industry distribution chart, Shenzhenlubris Pharmaceuticals Co ranks #400 out of 960 companies in the Drug Manufacturers industry, placing it in the top 41.7%.
Is Shenzhenlubris Pharmaceuticals Co's EBITDA Margin % too high?
Shenzhenlubris Pharmaceuticals Co's current EBITDA Margin % of 21.14% is 29% below median its 10-year median of 29.89. Over the past 10 years, this metric has ranged from a low of 11.70 to a high of 46.00. The Drug Manufacturers industry median EBITDA Margin % is 12.17. Shenzhenlubris Pharmaceuticals Co's value of 21.14% is 73.8% above this industry median. Based on the distribution chart, Shenzhenlubris Pharmaceuticals Co ranks #400 out of 960 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shenzhenlubris Pharmaceuticals Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shenzhenlubris Pharmaceuticals Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shenzhenlubris Pharmaceuticals Co ranks #400 out of 960 companies for EBITDA Margin %. This puts Shenzhenlubris Pharmaceuticals Co in the upper half of its industry. The industry median EBITDA Margin % is 12.17. Shenzhenlubris Pharmaceuticals Co's value of 21.14% is 73.8% above this benchmark. Historically, Shenzhenlubris Pharmaceuticals Co's own EBITDA Margin % has ranged from 11.70 to 46.00 over the past decade. While the company's 10-year median is 29.89 vs. the industry median of 12.17, Shenzhenlubris Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.17, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhenlubris Pharmaceuticals Co's current EBITDA Margin % of 21.14% is 73.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shenzhenlubris Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhenlubris Pharmaceuticals Co's current EBITDA Margin % is 21.14%, which is 29% below median its own 10-year median of 29.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhenlubris Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhenlubris Pharmaceuticals Co (SZSE:002294) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥44.01, compared to a current price of ¥33.85 — trading 23.1% below its estimated fair value. The current EBITDA Margin % is 21.14%, which is 29% below median its 10-year median of 29.89 and 73.8% above the Drug Manufacturers industry median of 12.17. Shenzhenlubris Pharmaceuticals Co's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Shenzhenlubris Pharmaceuticals Co (SZSE:002294), the current EBITDA Margin % is 21.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhenlubris Pharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥33.85 is trading 23.1% below its estimated GF Value™ of ¥44.01.
GuruFocus considers Shenzhenlubris Pharmaceuticals Co to be Modestly Undervalued.
Key valuation signals for SZSE:002294:
EBITDA Margin %: 21.14% (29% below median its 10-year median of 29.89)
GF Value™: ¥44.01 vs. price of ¥33.85 (23.1% below fair value)
Industry Position: 73.8% above the Drug Manufacturers median (#400 of 960)
No single metric tells the full story. See the SZSE:002294 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalosporins, and bone resorption inhibitors. Its products mainly focus on the areas of cardio-cerebral vascular disease, diabetes, complications, anti-tumor, and orthopedics. Its business lines include high-end chemical drugs, biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other countries and regions.
82GF Score
Get the complete analysis for SZSE:002294
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:002294 has been successfully added to your 
